“THE ROLE OF SMALL AIRWAYS IN OBSTRUCTIVE AIRWAY DISEASES”. P-R. BURGEL. EUR RESPIR REV 2011; 20: 23–33.
Unfortunately, the following dosing information in this article was presented incorrectly in the Therapeutic intervention in small airways disease section.
Papi and co-workers [71, 72] have shown that extrafine combination of BDP/formoterol was not inferior (as measured by morning peak expiratory flow in the last 2 weeks of a 12-week treatment) to non-extrafine combination of BDP/formoterol [71] and fluticasone/formoterol [72].
Huchon et al. [74] performed a 24-week study in 645 patients with moderate-to-severe asthma, comparing extrafine HFA-BDP/formoterol in a single inhaler to CFC-BDP in a single inhaler and to CFC-BDP and formoterol DPI administered via separate inhalers. HFA-BDP/formoterol was as effective as CFC-BDP plus formoterol DPI and was superior to CFC-BDP alone in improving lung function (as measured by morning peak expiratory flow).
The dosing information should have been presented in this section as follows.
Papi and co-workers [71, 72] have shown that extrafine combination of BDP/formoterol was not inferior (as measured by morning peak expiratory flow in the last 2 weeks of a 12-week treatment) to non-extrafine combination of budesonide/formoterol [71] and fluticasone/salmeterol [72].
Huchon et al. [74] performed a 24-week study in 645 patients with moderate-to-severe asthma, comparing extrafine HFA-BDP/formoterol in a single inhaler to CFC-BDP in a single inhaler and a combination of BDP and formoterol administered in larger particles via separate inhalers.
The following sentence was also incorrect: “In asthmatic patients, the dose of non-extrafine BDP required to achieve an improvement in lung function is 2.5 times higher than the dose of HFA-extrafine formulation required to produce the same increase in FEV1 [68].”
And should have read: “In asthmatic patients, the dose of conventional non-extrafine BDP required to achieve an improvement in lung function is 2.5 times higher than the dose of HFA-extrafine formulation required to produce the same increase in FEV1 [68].”
A corrected version of the manuscript is available online at err.ersjournals.com
- ©ERS 2011
